Other substances

Lenalidomide

A thalidomide derivative.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
7
 AI-suggested references
1
 Clinical trials

General information

Lenalidomide on DrugBank
Lenalidomide on PubChem

Marketed as

REVLIMID

 

Structure image - Lenalidomide

C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N

Supporting references

Link Tested on Impact factor Notes Publication date
Inhibition of SARS-CoV-2 main protease 3CLpro by means of α-ketoamide and pyridone-containing pharmaceuticals using in silico molecular docking
3CLpro Small molecule In silico 		in silico 2.46

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Jul/10/2020

AI-suggested references

Link Publication date
[Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.]
Dec/03/2020
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Jan/12/2022
Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
Mar/28/2022
Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action
Mar/15/2021
Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease
Jul/07/2020
Inhibition of SARS-CoV-2 main protease 3CLpro by means of alpha-ketoamide and pyridone-containing pharmaceuticals using in silico molecular docking.
Jul/10/2020
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study
Sep/06/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04361643 Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial Not yet recruiting Phase 4 Oct/27/2020 Dec/31/2021
  • Alternative id - COVID19-EC01
  • Interventions - Drug: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Universitario de Getafe, Getafe, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 120
  • Age - 60 Years and older   (Adult, Older Adult)
  • Outcome measures - Clinical improvement|Immune-inflammatory improvement|Mortality
Export (.csv)